Ultragenyx药业

Faruqi & Faruqi Investigating Ultragenyx Securities Class Action

Ultragenyx Pharmaceutical faces class-action lawsuit over misleading investor statements.

Ultragenyx

Ultragenyx Pharmaceutical Investors: Class Action Lawsuit Deadline Approaching on April 6, 2026

Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit: Investors Urged to Contact the Schall Law Firm

Ultragenyx's 15min chart shows MACD Death Cross and KDJ Death Cross.

Catalyst<ul> <li>A Strong Buy rating from the sole active analyst indicates institutional optimism about RARE.</li></ul>Risk<ul> <li>Bearish technical signals are currently dominant with no clear bullish direction emerging.</li> <li>Fund flows show negative trends across Small, Medium, and Large order sizes, indicating potential selling pressure.</li></ul>

Key Factors

Faruqi & Faruqi is investigating Ultragenyx Pharmaceutical Inc (RARE) for alleged securities violations between August 3, 2023, and December 26, 2025. Ultragenyx resubmitted its Biologics License Application for UX111 gene therapy in January 2026 with the FDA PDUFA action date expected in Q3 2026. Ultragenyx faces multiple class-action lawsuits over misleading investor statements regarding setrusumab's Phase III studies and drug efficacy.

RARE News